July 25, 2016 06:35 PM EDT
R&D
Pharma

What's Gilead­'s next deal go­ing to look like? CEO Mil­li­gan cites block­buster fil­go­tinib pact

John Carroll

Editor & Founder

Gilead to­day man­aged to sur­prise the an­a­lysts who fol­low the com­pa­ny by guid­ing down on its shrink­ing rev­enue for its megablock­buster hep C fran­chise …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Trump asks 'very tough hom­bre' Dr. Oz to lead MFN talks

US warns drug­mak­ers against mis­rep­re­sent­ing cost of im­port­ed prod­ucts

End­points 100 biotech sur­vey: Wel­come to the sum­mer of biotech’s dis­con­tent

About 5% of CBER and CDER left af­ter FDA staff cuts, analy­sis finds

Big leas­es, big­ger re­grets: Biotech slump turns swanky of­fices from as­set in­to li­a­bil­i­ty

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times